Tags

Type your tag names separated by a space and hit enter

The effect of coenzyme Q10 in patients with congestive heart failure.
Ann Intern Med. 2000 Apr 18; 132(8):636-40.AIM

Abstract

BACKGROUND

Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies. Few randomized, blinded, controlled studies have evaluated objective measures of cardiac performance.

OBJECTIVE

To determine the effect of coenzyme Q10 on peak oxygen consumption, exercise duration, and ejection fraction.

DESIGN

Randomized, double-blind, controlled trial.

SETTING

University and Veterans Affairs hospitals.

PATIENTS

55 patients who had congestive heart failure with New York Heart Association class III and IV symptoms, ejection fraction less than 40%, and peak oxygen consumption less than 17.0 mL/kg per minute (or <50% of predicted) during standard therapy were randomly assigned. Forty-six patients completed the study.

INTERVENTION

Coenzyme Q10, 200 mg/d, or placebo.

MEASUREMENTS

Left ventricular ejection fraction (measured by radionuclide ventriculography) and peak oxygen consumption and exercise duration (measured by a graded exercise evaluation using the Naughton protocol) with continuous metabolic monitoring.

RESULTS

Although the mean (+/-SD) serum concentration of coenzyme Q10 increased from 0.95+/-0.62 microg/mL to 2.2+/-1.2 microg/mL in patients who received active treatment, ejection fraction, peak oxygen consumption, and exercise duration remained unchanged in both the coenzyme Q10 and placebo groups.

CONCLUSION

Coenzyme Q10 does not affect ejection fraction, peak oxygen consumption, or exercise duration in patients with congestive heart failure receiving standard medical therapy.

Authors+Show Affiliations

University of Maryland School of Medicine and Veterans Affairs Medical Center, Baltimore 21201, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10766682

Citation

Khatta, M, et al. "The Effect of Coenzyme Q10 in Patients With Congestive Heart Failure." Annals of Internal Medicine, vol. 132, no. 8, 2000, pp. 636-40.
Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132(8):636-40.
Khatta, M., Alexander, B. S., Krichten, C. M., Fisher, M. L., Freudenberger, R., Robinson, S. W., & Gottlieb, S. S. (2000). The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine, 132(8), 636-40.
Khatta M, et al. The Effect of Coenzyme Q10 in Patients With Congestive Heart Failure. Ann Intern Med. 2000 Apr 18;132(8):636-40. PubMed PMID: 10766682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of coenzyme Q10 in patients with congestive heart failure. AU - Khatta,M, AU - Alexander,B S, AU - Krichten,C M, AU - Fisher,M L, AU - Freudenberger,R, AU - Robinson,S W, AU - Gottlieb,S S, PY - 2000/4/15/pubmed PY - 2000/9/8/medline PY - 2000/4/15/entrez SP - 636 EP - 40 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 132 IS - 8 N2 - BACKGROUND: Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies. Few randomized, blinded, controlled studies have evaluated objective measures of cardiac performance. OBJECTIVE: To determine the effect of coenzyme Q10 on peak oxygen consumption, exercise duration, and ejection fraction. DESIGN: Randomized, double-blind, controlled trial. SETTING: University and Veterans Affairs hospitals. PATIENTS: 55 patients who had congestive heart failure with New York Heart Association class III and IV symptoms, ejection fraction less than 40%, and peak oxygen consumption less than 17.0 mL/kg per minute (or <50% of predicted) during standard therapy were randomly assigned. Forty-six patients completed the study. INTERVENTION: Coenzyme Q10, 200 mg/d, or placebo. MEASUREMENTS: Left ventricular ejection fraction (measured by radionuclide ventriculography) and peak oxygen consumption and exercise duration (measured by a graded exercise evaluation using the Naughton protocol) with continuous metabolic monitoring. RESULTS: Although the mean (+/-SD) serum concentration of coenzyme Q10 increased from 0.95+/-0.62 microg/mL to 2.2+/-1.2 microg/mL in patients who received active treatment, ejection fraction, peak oxygen consumption, and exercise duration remained unchanged in both the coenzyme Q10 and placebo groups. CONCLUSION: Coenzyme Q10 does not affect ejection fraction, peak oxygen consumption, or exercise duration in patients with congestive heart failure receiving standard medical therapy. SN - 0003-4819 UR - https://www.unboundmedicine.com/medline/citation/10766682/The_effect_of_coenzyme_Q10_in_patients_with_congestive_heart_failure_ L2 - https://www.annals.org/aim/fullarticle/doi/10.7326/0003-4819-132-8-200004180-00006 DB - PRIME DP - Unbound Medicine ER -